Overview

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Ophthotech Corporation
Treatments:
Aflibercept
Bevacizumab
Ranibizumab